Document Type : Original Article
Authors
- . Lalit Prashant Meena
- . Shant Kumar Pandey
- . Madhukar Rai
- . Anju Bharti
- . Jaya Chakravarty
- . Shyam Sundar
Department of Pathology, King George’s Medical University, Lucknow, Uttar Pradesh, India
Abstract
Background: Majority of HIV/AIDS patients who are on Highly Active Anti Retroviral Therapy
(HAART), are not aware about drug adherence and its importance which is the most important
factor for drug adherence. Objectives: To study the level of drug adherence in patients accessing
antiretroviral therapy (ART) through the National program and factor influencing drug adherence.
Materials and Methods: In present study, we enrolled 102 newly diagnosed patients, among
them in 79 patients, ART was started. To study the drug adherence a pretested, semistructured
questionnaire was formed and patients were followed up for 6 months of the study. Pretest and
posttest counseling was done to all such patients. Results: A total of 28 patients missed the
dose in 1st follow-up, nine patients missed in 2nd follow-up, eight patients missed in 3rd follow-up.
Three patients lost follow-up in 2nd follow-up, three patients further lost follow-up in 3rd follow-up.
Running out of pills (40.0%), side effect (15.5%), and family problem (13.3%), poor transport
facility for taking drug (8.9%) and forgetfulness (11.1%) are five major causes related to miss
dose. In females patients, drug adherence (69%) was initially less than male patients (76%) but
latter on female patients (96.3%) had better adherence than males (95.2%). Conclusion: This
study suggest that drug adherence can be increased by proper counseling and close monitoring
of the patients which may have a great role in preventing the drug resistance and ART response.
Keywords
Philadelphia: Churchill Livingstone Elsevier publication; 2007.
2. Stone VE. Strategies for optimizing adherence to highly active
antiretroviral therapy: Lessons from research and clinical practice.
Clin Infect Dis 2001;33:865-72.
3. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of
antiretrovirals in resource-poor settings: Prevention of HIV infection
whilst controlling drug resistance. Curr Drug Targets Infect Disord
2003;3:345-53.
4. Friedland GH, Williams A. Attaining higher goals in HIV treatment:
The central importance of adherence. AIDS 1999;13:61-72.
5. Paterson DL, Swindells S, Mohr J, Brester M, Vergis E, Squire C,
et al. Adherence to protease inhibitor therapy and outcomes in
patients with HIV infection. Ann Intern Med 2000;133:21-30.
6. Antiretroviral therapy guidelines for HIV-infected adults and
adolescents including post-exposure prophylaxis. Ministry of
Health and Family Welfare, Department of AIDS Control, May 2007.
Available from: http://www.nacoonline.org/. [Last accessed on 2011
Sept 30].
7. Wang X, Yang L, Li H, Zuo L, Liang S, Liu W, et al. Factors
associated with HIV virologic failure among patients on HAART
for one year at three sentinel surveillance sites in China. Curr HIV
Res 2011;9:103-11.
8. El-Khatib Z, Katzenstein D, Marrone G, Laher F, Mohapi L, Petzold
M, et al. Adherence to drug-refill is a useful early warning indicator
of virologic and immunologic failure among HIV patients on first-line
ART in South Africa. PLoS One 2011;6:e17518.
9. Patel A, Hirschhorn L, Fullem A, Ojikutu B, Oser R. Adult aherence
to treatment and retention in care. Arlington, VA: USAID|AIDSTARONE PROJECT, Task Order 1; 2010. Available from: http://cdn2.
brhc.com/gh/wp-content/uploads/2013/03/21_AdultAdherenceTB_
Final.pdf. [Last accessed on 2014 February 23]
10. CMIS Bulletin, (April 2008 to Sept 2008). National AIDS Control
Organization, Department of AIDS Control, Ministry of Health and
Family Welfare, Government of India. Available from: http://www.
nacoonline.org/upload/Care%20&%20 Treatment/functional%20
LAC%20centers%20July%202010.pdf. [Last accessed on 2011
April 13].
11. Sahay S, Ghate M, Mehendale S. Managing HIV Therapy literacy in
resource- limited settings. HIV Ther 2009;3:339-44.
12. Sankar A, Golin C, Simoni JM, Luborsky M, Pearson C. How
qualitative methods contribute to understanding combination
antiretroviral therapy adherence. J Acquir Immune Defic Syndr
2006;43:S54-68.
13. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P,
et al. Adherence to HAART: A systematic review of developed anddeveloping nation patient-reported barriers and facilitators. PLoS
Med 2006;3:e438.
14. Knobel H, Carmona A, Geular A. Adherence in patients treated with
HAART: Influence in hospital admissions. In: Program and abstracts
of the XIII International AIDS Conference; July 9-14, 2000; Durban,
South Africa.
15. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M,
Zolopa AR, et al. Non-adherence to highly active antiretroviral
therapy predicts progression to AIDS. AIDS 2001;15:1181-3.
16. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The
consistency of adherence to antiretroviral therapy predicts biologic
outcomes for human immunodeficiency virus-infected persons in
clinical trials. Clin Infect Dis 2002;34:1115-21.
17. Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P,
et al. A prospective study of adherence and viral load in a large
multi-center cohort of HIV-infected women. AIDS 2002;16:
2175-82.
18. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J,
Zwickl B, et al. Self-reported adherence to antiretroviral medications
among participants in HIV clinical trials: The AACTG adherence
instruments. Patient Care Committee and Adherence Working Group
of the Outcomes Committee of the Adult AIDS Clinical Trials Group
(AACTG). AIDS Care 2000;12:255-66.
19. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi
PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+
Ugandan patients purchasing therapy. Int J STD AIDS 2005;16:38-41.
)